Cargando…
HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis, and gemcitabine-based chemotherapy remains an effective option for the majority of PDAC patients. Hepatocyte nuclear factor 1α (HNF1A) is a tumor-suppressor in PDAC, but its role in gemcitabine chemores...
Autores principales: | Lu, Yanan, Xu, Dongni, Peng, Jintao, Luo, Zhaofan, Chen, Chujie, Chen, Yuqing, Chen, Huimou, Zheng, Minghui, Yin, Peihong, Wang, Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606897/ https://www.ncbi.nlm.nih.gov/pubmed/31103629 http://dx.doi.org/10.1016/j.ebiom.2019.05.013 |
Ejemplares similares
-
Hepatocyte Nuclear Factor 1A (HNF1A) as a Possible Tumor Suppressor in Pancreatic Cancer
por: Luo, Zhaofan, et al.
Publicado: (2015) -
Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
por: Bai, Zhiqing, et al.
Publicado: (2022) -
The HNF1α-regulated lncRNA HNF1A-AS1 reverses the malignancy of hepatocellular carcinoma by enhancing the phosphatase activity of SHP-1
por: Ding, Chen-Hong, et al.
Publicado: (2018) -
Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine
por: Yin, Tao, et al.
Publicado: (2016) -
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong, Dao-Jun, et al.
Publicado: (2013)